BioSight
Therapeutics for Oncology and Hematological Disorders
Company Overview
Snapshot
Founded in November 1999 by Stela Gengrinovitch, PhD and Mark Gengrinovitch, BioSight operates with 1–10 employees. The company raised a total of $62.5M across 5 funding rounds from 9 investors. In October 2023, BioSight was acquired by Ayala Pharmaceuticals.
Business overview
BioSight is a clinical-stage biotechnology company focused on developing therapeutics for hematological malignancies and disorders. Its core product, BST-236 (aspacytarabine), is an anti-metabolite designed for high-dose therapy with reduced systemic toxicity. The company operates within the Health Tech & Life Sciences sector, specifically targeting the pharmaceutical industry with its oncology and hematology treatments.
Strategic signal
In November 2022, BioSight launched a Phase 1/2 clinical trial for aspacytarabine in combination with venetoclax for first-line AML induction therapy, followed by aspacytarabine consolidation. This initiative signals the company's continued commitment to advancing its lead product and exploring combination therapies to enhance treatment efficacy for acute myeloid leukemia, demonstrating ongoing clinical development and potential for market expansion prior to its acquisition.
Log in to access full profile ›Company Intelligence Q&A
- What was BioSight's most recent significant corporate event?
- In October 2023, BioSight was acquired by Ayala Pharmaceuticals, marking a significant exit for the company.
- When did BioSight last raise a funding round?
- In December 2020, BioSight closed a Series C financing round. The round was led by Israel Biotech Fund and joined by Arkin Bio.
- What was a key regulatory milestone for BioSight's lead product?
- In August 2020, BioSight was granted U.S. FDA Fast Track Designation for BST-236 for the treatment of Acute Myeloid Leukemia, accelerating its development and review process.
- Did BioSight receive any other special designations for BST-236?
- Yes, in June 2019, BioSight received Orphan Drug Designation from the FDA for BST-236 for the treatment of Acute Myeloid Leukemia.
- What was a notable clinical development for BioSight?
- In November 2022, BioSight launched a Phase 1/2 clinical trial of aspacytarabine in combination with venetoclax for first-line AML induction therapy, followed by aspacytarabine consolidation.